Abbvie 1Q Results

Abbvie
1Q Revenues: $12.3 billion (+1%)
1Q Earnings: $1.4 billion (earnings were $239 million 1Q23)
Comments: Immunology portfolio sales were $5.4 billion, down 4% in the quarter. Global Humira sales were $2.3 billion down 36%. Global Skyrizi revenues were $2.0 billion, an increase of 48% and global Rinvoq revenues were $1.1 billion, an increase of 59%. Oncology portfolio sales were $1.5 billion, an increase of 9%. Global Imbruvica sales were $838 million, down 5%. Global Venclexta sales were $614 million, up 14%. Global Elahere sales were $64 million, reflecting a partial quarter of sales based on the February 2024 close date of the ImmunoGen acquisition. Global neuroscience portfolio sales were $1.96 billion, an increase of 16%. Global Botox Therapeutic sales were $748 million, up 4%. Global Vraylar sales were $694 million, up 24%. Global Ubrelvy revenues were $203 million, an increase of 34%. Global Qulipta sales were $131 million, an increase of 98%. Global revenues from the aesthetics portfolio were $1.2 billion, a decrease of 4%.
Global Botox Cosmetic sales were $633 million, down 4%. Global Juvederm revenues were $297 million, a down 16%.